ASCO 2020 Begins with an Exciting Motto: ‘‘Unite and Conquer: Let’s Accelerate Progress Together!’’

ASCO 2020 Scientific Program's main motto seems likely to resonate even more strongly this year despite the circumstances we face. ASCO's global audience will learn about new developments in cancer through more than 250 oral presentations and more than 2500 poster presentations in 24 areas organized by subspecialty and disease.
On 30 May at 09:30 US Eastern Time, ASCO President Dr. Howard. A Skip Burris III (MD, FASCO, FACP) will deliver the opening address. Dr. Burris noted that although the format of ASCO20 has changed because of COVID-19, the shared determination to make progress against cancer is as strong as ever.
Dr. Burris says that when he chose the main motto for the 2020 meeting, ‘‘Unite and conquer: Let’s accelerate progress together!’’, he never imagined that this spring people would be unable to gather in person for a meeting held face to face for the past 55 years. He adds: ‘‘Although we are physically apart, we are all united in our determination to provide the best possible care for every patient with cancer and to make progress against cancer despite every obstacle, including the sudden challenges brought by COVID-19!’’.
In his address, Dr. Burris will share highlights from his experiences as ASCO President during 2019-2020. These experiences confirm something he has known for a long time: real progress against cancer is made when unity and solidarity accompany strong leadership in efforts to develop treatments, continue clinical trials, establish effective oncology practice, and achieve better outcomes for patients.
The COVID-19 pandemic has changed how patients with cancer access healthcare. It has affected the way medical oncologists and patients with cancer weigh the risks and benefits of delaying treatment under these circumstances. The impact of the global pandemic will continue to grow until an effective treatment or vaccine is developed.
This Year's Opening Address Will Resonate Strongly

This year's guest speaker at the opening session, David Fajgenbaum, MD, MBA, MSc, understands better than most the lack of a definitive cure for a fatal disease and the uncertainty it brings. His bestselling autobiography, written in 2019 and originally titled ‘’Chasing My Cure: A Doctor’s Race to Turn Hope into Action (In Search of a Cure: A Doctor's Race to Turn Hope into Action; the book has not yet been translated into Turkish)’’, recounts his experiences. Dr. Fajgenbaum will discuss his relentless journey to find a cure for the rare disorder Castleman disease, his extraordinary struggle to hold on to life after nearly dying five times, and some of the views and beliefs that matter to him.
Dr. Fajgenbaum believes that the methods he pioneered in groundbreaking research into his own illness, idiopathic Castleman disease (whose cause and etiology have not been established), will help develop treatments to cope with the current pandemic. Like coronavirus infection, Castleman disease can cause a cytokine storm (activity of the immune system far greater than it should be).
Dr. Fajgenbaum is an associate professor of Translational Medicine (the field of medical science that bridges basic and clinical sciences) and Human Genetics. At the University of Pennsylvania, he leads the Castleman Disease Collaborative Network as well as the Center for the Study and Treatment of Lymphadenopathy and Cytokine Storms. He is also associate director of the Pennsylvania Orphan Disease Center.
Following in the footsteps of Atul Gawande, MD, MPH, and Siddhartha Mukherjee, MD, DPhil, the guest speakers will address issues that matter to everyone in the midst of the pandemic. They will share the importance of focusing on what matters in life and finding ways to turn fear into positive action. We hope ASCO 2020 brings inspiration and hope to everyone.
Sources
dailynews.ascopubs.org - 26 May 2020
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.